No abstract available
MeSH terms
-
Adalimumab
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antitubercular Agents / therapeutic use*
-
Crohn Disease / diagnosis
-
Crohn Disease / drug therapy*
-
Crohn Disease / immunology
-
Drug Administration Schedule
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects*
-
Latent Tuberculosis / diagnosis
-
Latent Tuberculosis / drug therapy
-
Latent Tuberculosis / immunology
-
Latent Tuberculosis / microbiology*
-
Male
-
Mycobacterium tuberculosis / drug effects
-
Mycobacterium tuberculosis / immunology
-
Mycobacterium tuberculosis / pathogenicity*
-
Opportunistic Infections / diagnosis
-
Opportunistic Infections / drug therapy
-
Opportunistic Infections / immunology
-
Opportunistic Infections / microbiology*
-
Recurrence
-
Risk Factors
-
Time Factors
-
Treatment Outcome
-
Tuberculosis, Pulmonary / diagnosis
-
Tuberculosis, Pulmonary / drug therapy
-
Tuberculosis, Pulmonary / immunology
-
Tuberculosis, Pulmonary / microbiology*
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Young Adult
Substances
-
Antibodies, Monoclonal, Humanized
-
Antitubercular Agents
-
Immunosuppressive Agents
-
Tumor Necrosis Factor-alpha
-
Adalimumab